Physician profile
Daniel Kapner
NPI 1467870865
$2,904.90
in general payments reported to CMS, 2019-2025
21 companies · $467 in 2025
The $467 reported for 2025 was more than what 78% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $190 · 2021: $522 · 2022: $395 · 2023: $412 · 2024: $632 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $636.71 | 2022-2025 | |
| Scilex Pharmaceuticals INC. | $516.79 | 2019-2025 | Ztlido |
| Allergan, INC. | $263.45 | 2021-2022 | |
| Relievant Medsystems, INC. | $235.43 | 2021-2023 | Intracept |
| Medtronic USA, INC. | $209.58 | 2019 | |
| Medtronic, INC. | $187.25 | 2024-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Redhill Biopharma INC. | $161.97 | 2020-2022 | |
| Averitas Pharma INC. | $142.36 | 2023-2025 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.56 | 2020-2025 | Relistor |
| Valinor Pharma, LLC | $78.13 | 2023-2025 | Movantik |
| Pfizer INC. | $75.56 | 2019-2021 | |
| Boston Scientific Corporation | $48.40 | 2019-2020 | |
| Horizon Therapeutics Plc | $46.08 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $40.47 | 2020 | |
| Ferring Pharmaceuticals INC. | $23.49 | 2024 | Euflexxa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $23.11 | 2023 | Cologuard Collection Kit |
| Zimmer Biomet Holdings, INC. | $21.40 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Baudax Bio INC. | $19.90 | 2020 | |
| Ibsa Pharma INC. | $17.05 | 2021 | |
| Depuy Synthes Sales INC. | $14.97 | 2021 | |
| Assertio Therapeutics, INC. | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kapner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.